A robust antibody discovery platform is an important core factor that determines the success of a set of drug modalities. The area of antibody discovery has seen tremendous technological advancement, offering pharma companies a wide range of tools to choose from. At Aurigene, we design our antibody discovery programs keeping the therapeutic end point in mind and choose the technology platform accordingly.
Our team has experience in handling several technology platforms including humanized rodents, B-cell cloning, hybridoma and display libraries. Fit-for-purpose tools and reagent antibodies are generated to meet the program needs.
Antigen Generation and Immunization strategies
- RNA, membrane and whole cell immunization
- Immunization with conjugate antigens
- Immunization with whole-cell, recombinant cell lines, nano disc and membrane preparations
- Immunization protocols: standard, RImMS and hybrid
- Neonatal strategy for better epitope specificity and less immunogenic epitope
- Strong expertise in anti-idiotypic antibody discovery (blockers/non-blockers with single digit nM/pM affinity) to support PK / ADA assays
Hybridoma and B-Cell Cloning
- Antigen-specific single B-cell sorting, sequencing / v-gene recovery, sub-cloning / reformatting, expression, screening and monoclonal selection
- Enriched B cell or target-specific B cell fusion methodologies
- Highly efficient and optimized fusion (PEG and electrofusion) technologies for generating hybridoma
Screening and Evaluation Strategies
- Multitier high-throughput screening strategies using flow cytometry, ELISA and octet
- Analytical SE-HPLC, BIAcore, functional assay and mass spectrometry to support analytics
- Functional assay and fit-for-purpose assay (IHC, Western blotting etc.) for evaluation
Why Aurigene Pharmaceutical Services?
Single B-cell cloning
Humanized rodent platform
Display platforms (Phage/ Yeast)
Hybridoma
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Resources
APRIL 24, 2023
The importance of business continuity planning in CRDMO industry
Both natural and unnatural catastrophic events inflict negative consequences due to the ever-increasing interconnectedness of the global economy. Those consequences are certain to last for longer duration. e.g.; The Covid-19 pandemic is still having a negative impact on the global economy. Maintaining continuity is critical for all businesses, but perhaps no othe...
Read More
Evolution in Pharma Industry and Demand for Integrated CDMO
The pharma industry is evolving and a demand for integrated CDMOs, which can help accelerating innovations, is part of the evolution....
Read More
cGMP Development and Manufacturing Services
Aurigene Pharmaceutical Services has a legacy of +20 years in developing and manufacturing compounds under cGMP. Our manufacturing plants are spread across 3 continents with facilities in India, UK, and Mexico. ...
Read More
Systematic formulation design - shorten development cost & time
Project Challenge: Existing formulation (lower strength - 50 mg) was manufactured using direct compression process. This formulation posed poor powder flow and content uniformity issues during scale-up. Development of new strength 150 mg without any process issues was a challenge. Solution design: Preliminary pre-formulation, stress study and PSD impact assessmen...
Read More
Synthesis of 2-hydroxy-3-alkyl-2-phenyl-2,3- dihydroquinazolin-4(1H)-one via molybdenum hexacarbonyl mediated CO gas- and ligand free carbonylative reactions
2016
Carbon monoxide gas and ligand-free conditions were developed for the synthesis of 2-hydroxy-3-alkyl-2-phenyl-2,3-dihydroquinazolin4(1H)-one via catalytic carbonylation with molybdenum hexacarbonyl as an efficient carbonylating agent for the three-component reaction of isatoic anhydride, amine, iodobenzene. Mo(CO)6 is a solid carbon monoxide source. The quinazoli...
Read More-
Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2005
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More -
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2005
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.